[lurkingforacure]

for bipolar disorder. What was interesting is that the study was clearly contemplating long term use of MB for those afflicted with bipolar disorder, so they must consider it safe for long term use (I have read some comments where the author cautioned against long term use). This study recruited in 2005 and has been completed, and was a Phase III! But I cannot find out more.

Our Canadian friends, any suggestions on how to follow up? Here's the link:
http://clinicaltrials.gov/ct2/show/NCT00214877

Also have read some articles using MB in various scenarios successfully, to wit: (I never get to use that phrase!)

after cardiac surgery where the patient goes into cardiac arrest
where there has been a neurological assult by a toxin, MB has been used to restore normal function (there were some indications recovery would have occurred anyway, since it did in some patients with the mere passage of time, but still...) malaria, etc. This could have some real potential, even if it only slows progression.

I'd really like to find out what happened in this study, if anyone can help. Thanks!

[lurkingforacure]

Dr. Atamna, who was one of the authors of the 2008 MB study in Oakland that was cited earlier here on NT, has moved on to the Commonwealth Medical College in Pennsylvania.

His lab is very focused on aging with a particular emphasis on the mitochondria, and on the website of Commonwealth his research work is listed. Here's the website link to his research areas:

http://www.thecommonwealthmedical.co...geID=OTH000232

Here's the snippet related to MB, which I found very encouraging as he (briefly) discusses follow-up work to that he did when he was at Oakland and did the MB study funded by Dr. Bruce Ames:

"New, safe, and potent anti aging drug;
Follow up research in this direction in my lab has identified an additional class of anti-aging agents; the diaminophenothiazines. Methylene blue (MB) is the most active and relevant to human. MB protects mitochondria in vivo and in vitro at efficiency that exceeded NtBHA by 1000 folds. This new class of anti-aging agents reversed the decline in cognitive performance and muscle strength in old mice. My lab is investigating the mechanism of action of these agents. Based on the experimental results, I believe that these agents participate in oxidation-reduction reactions at the level of the mitochondrial electron transport chain (e.g. complex I & IV). This interaction prevents the formation of superoxide radicals, protects the mitochondria from oxidative damage, and promotes mitochondrial biogenesis.
Our eventual goal is to use these agents to prevent the production of free radicals and the mitochondrial dysfunction associated with age-related disabilities. My lab currently is actively searching for nutriceutical that may mimic the action of these drugs. We have made a humble success in this direction."

Thoughts?